# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a n...
Brookline Capital analyst Kumaraguru Raja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and anno...
The SAB Board of Directors has launched a formal search process to identify King's permanent replacement. Mark Conley, SAB&...
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $25 price target.